# National Institute for Health and Care Excellence

# Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management

## [E1] Evidence review for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae

*NICE guideline number tbc*

*Evidence reviews underpinning recommendations 1.6.4, 1.6.10 and 1.6.16 in the NICE guideline*

*September 2023*

NICE accredited
www.nice.org.uk/accreditation

**Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

# Contents

# 1 Antibiotics for bacterial meningitis caused 2 by Streptococcus pneumoniae

## 3 Review question

4 What antibiotic treatment regimens are effective in treating bacterial meningitis caused by 5 Streptococcus pneumoniae?

## 6 Introduction

7 Bacterial meningitis is a rare but serious infection. The causative organism is usually 8 confirmed by tests performed on cerebrospinal fluid or blood samples. Streptococcus 9 pneumoniae is a common cause of bacterial meningitis in most age groups.

10 The aim of this review is to determine what antibiotic treatment regimens are effective in 11 treating bacterial meningitis caused by Streptococcus pneumoniae.

## 12 Summary of the protocol

13 See Table 1 for a summary of the Population, Intervention, Comparison and Outcome 14 (PICO) characteristics of this review.

15 **Table 1:  Summary of the protocol (PICO table)**

| Population | All adults, young people, children and babies (excluding neonates defined as aged 28 days old and younger) with confirmed bacterial meningitis caused by Streptococcus pneumoniae |
|---|---|
| Intervention | Antibiotic agent of interest: <br>• Cefotaxime <br>• Ceftriaxone <br>• Chloramphenicol <br>• Ciprofloxacin <br>• Moxifloxacin <br>• Levofloxacin <br>• Benzylpencillin sodium <br>• Ampicillin <br>• Amoxicillin <br>• Meropenem <br>• Linezolid <br>• Daptomycin <br>• Co-trimoxazole <br>• Rifampicin <br>• Vancomycin |
| Comparison | **Stage 1 (all antibiotic agents of interest):** <br>• Antibiotic agent A (single or combination)* vs Antibiotic agent B (single or combination)* <br>*Rifampicin and vancomycin to be used in combination with other antibiotics not as monotherapy. <br>**Stage 2 (antibiotic agents identified during stage 1 as most effective/for use where there are contraindications)** |

| | |
|---|---|
| | Comparisons:<br>• Antibiotic agent A – Dose A vs Antibiotic agent A – Dose B<br>• Antibiotic agent A – Duration of administration A vs Antibiotic agent A – Duration of administration B<br>• Antibiotic agent A – Short infusion vs Antibiotic agent A – Extended infusion |
| **Outcome** | **Critical**<br>Population: adults, children and infants<br>• All-cause mortality (measured up to 1 year after discharge)<br>• Any long-term neurological impairment (defined as any motor deficits, sensory deficits [excluding hearing impairment], cognitive deficits, or behavioural deficits; measured from discharge up to 1 year after discharge)<br>Population: adults<br>• Functional impairment (measured by any validated scale at any time point)<br>Population: children and infants<br>• Severe developmental delay (defined as score of >2 SD below normal on validated assessment scales, or MDI or PDI <70 on Bayleys assessment scale, or inability to assign a score due to cerebral palsy or severity of cognitive delay; measured at the oldest age reported unless there is substantially more data available at a younger age)<br><br>**Important**<br>Population: adults, children and infants<br>• Hearing impairment (defined as any level of hearing impairment; measured from discharge up to 1 year after discharge)<br>• Serious intervention-related adverse effects leading to death, disability or prolonged hospitalisation or that are life threatening or otherwise considered medically significant<br>• CSF sterilisation (defined as treatment failure, time-to-sterilisation or delay)<br>Population: adults<br>• Intracranial collections as a complication (defined as abscess or empyema)<br>Population: children and infants<br>• Functional impairment (measured by any validated scale at any time point)<br>*For infants and children below school-age, cognitive and behavioural deficits will be assessed at school-age. |

*CSF: cerebrospinal fluid; MDI: mental development index; PDI: psychomotor development index; SD: standard deviation*

For further details see the review protocol in appendix A.

## Methods and process

This evidence review was developed using the methods and process described in Developing NICE guidelines: the manual. Methods specific to this review question are described in the review protocol in appendix A and the methods document (supplementary document 1).

Declarations of interest were recorded according to NICE's conflicts of interest policy.

## Effectiveness evidence

## Included studies

One randomised controlled trial was included for this review (Molyneux 2011).

1   The included study is summarised in Table 2.

2   The study (Molyneux 2011) compared 5-day ceftriaxone therapy to 10-day ceftriaxone
3   therapy in babies and children.

4   See the literature search strategy in appendix B and study selection flow chart in appendix C.

5   **Excluded studies**

6   Studies not included in this review are listed, and reasons for their exclusion are provided in
7   appendix J.

8   **Summary of included studies**

9   Summary of the study that was included in this review are presented in Table 2.

10  **Table 2:  Summary of the included study**

| Study | Population | Intervention | Comparison | Outcomes | Comments |
|-------|-----------|--------------|------------|----------|----------|
| Molyneux 2011<br><br>RCT<br><br>Bangladesh, Egypt, Malawi, Pakistan and Vietnam | N=1004*<br><br>Streptococcus pneumoniae n=335<br><br>Children aged 2 months to 12 years with bacterial meningitis caused by Haemophilus influenzae (n=266), Streptococcus pneumoniae (n=335), or Neisseria meningitides (n=73) (no cause identified (n=330)**<br><br>Age in months (mean; SD in parentheses): 38.2 (42)<br><br>Population treated with dexamethasone therapy: 43.5%<br><br>Case-fatality: | 5-day ceftriaxone therapy (n=496)<br><br>IV ceftriaxone 80-100 mg/kg once daily for 5 days | 10-day ceftriaxone therapy (n=508)<br><br>IV ceftriaxone 80-100 mg/kg once daily for 10 days | • All-cause mortality<br>• Any long-term neurological impairment<br>• Developmental delay<br>• Hearing impairment<br>• Serious intervention-related adverse effects<br>• CSF sterilisation | Population is indirect for all outcomes except for all-cause mortality and CSF sterilisation due to 66% of population with meningitis caused by organisms other than S. pneumoniae |

| Study | Population | Intervention | Comparison | Outcomes | Comments |
|---|---|---|---|---|---|
| | 4.1% | | | | |

*IV: intravenous; RCT: randomised controlled trial; SD: standard deviation; S. pneumonia: Streptococcus pneumonia*
*Patients' characteristics and all outcomes (except all-cause mortality and CSF sterilisation) reported on all study and not based on causative organism
**Only bacterial meningitis caused by S. pneumonia is of interest for this review

See the full evidence tables in appendix D. No meta-analysis was conducted (and so there are no forest plots in appendix E).

## Summary of the evidence

This section is a narrative summary of the findings of the review, as presented in the GRADE tables in appendix F. For details of the committee's confidence in the evidence and how this affected recommendations, see the committee's discussion and interpretation of the evidence.

The evidence was assessed as being very low quality due to risk of bias (arising from missing outcome data), imprecision (due to low event rates), and indirectness (in terms of population and some outcomes).

The evidence showed no important differences between 5-day and 10-day ceftriaxone treatment for all-cause mortality, neurological impairment, developmental delay, hearing impairment, serious intervention-related adverse effects, or cerebrospinal fluid (CSF) sterilisation.

No eligible studies were identified that reported functional impairment, or intracranial collections as a complication.

No evidence was available that compared the effectiveness of different antibiotic agents, different doses, or short infusion relative to extended infusion, for the treatment of bacterial meningitis caused by Streptococcus pneumoniae.

See appendix F for full GRADE tables.

## Economic evidence

### Included studies

A single economic search was undertaken for all topics included in the scope of this guideline, but no economic studies were identified which were applicable to this review question.

### Economic model

No economic modelling was undertaken for this review because the committee agreed that other topics were higher priorities for economic evaluation.

## The committee's discussion and interpretation of the evidence

### The outcomes that matter most

Bacterial meningitis is associated with high rates of mortality and morbidity, and antibiotics are the mainstay of treatment for bacterial meningitis. Therefore, all-cause mortality and

1 long-term neurological impairment were prioritised as critical outcomes due to the severity of
2 these outcomes. Severe developmental delay was prioritised over functional impairment in
3 children and babies, as it is a more relevant and important outcome for this population.
4 Functional impairment was prioritised as a critical outcome in adults due to the concern
5 about the potential long-term limitations of bacterial meningitis on the ability to carry out
6 certain activities of daily life.

7 In addition to functional impairment (in children and babies), hearing impairment, serious
8 intervention-related adverse effects, and cerebrospinal fluid (CSF) sterilisation were selected
9 as important outcomes in all age groups as these are relatively common after bacterial
10 meningitis and may be related to antibiotic therapy. Intracranial collections as a complication
11 was also included as an important outcome for adults as this is a rare but severe and life
12 threatening complication of bacterial meningitis that may require prolonged antibiotic
13 treatment.

14 **The quality of the evidence**

15 The quality of the evidence was assessed using GRADE methodology. The evidence for all
16 outcomes in this review was very low quality, and the main reasons evidence was
17 downgraded were risk of bias (for example, bias arising from subjective measurement of
18 outcome, and missing outcome data), imprecision (due to wide confidence intervals and
19 small number of events), and indirectness (due to the population including people with
20 meningitis caused by organisms other than Streptococcus pneumoniae, and some composite
21 outcomes).

22 No evidence was found for functional impairment, or intracranial collections as a
23 complication.

24 **Benefits and harms**

25 No evidence was identified comparing the effectiveness of different antibiotics for the
26 treatment of meningitis caused by Streptococcus pneumoniae. Based on their clinical
27 knowledge and experience, and on current practice, the committee recommended
28 ceftriaxone in line with the BNF (Joint Formulary Committee 2022) and BNFC (Paediatric
29 Formulary Committee 2022), for the treatment of Streptococcus pneumoniae meningitis.

30 The committee highlighted the practical and resource-use advantages associated with
31 ceftriaxone because the long half-life means that it may be given only once a day. The
32 committee acknowledged some concerns with once daily administration in that a second
33 dose might need to be delayed if the first dose of ceftriaxone was administered outside of
34 routine working hours; however, they were aware that a second dose can be given earlier, to
35 shift the administration time, if there is a minimum of 12 hours between doses (Gbesemete
36 2019).

37 The committee discussed some reasons why in clinical practice (particularly in intensive care
38 units) cefotaxime might be given instead of ceftriaxone. For instance, to minimise the time
39 that intravenous lines are being used for administering antibiotics, which might be needed for
40 other medications, due to ceftriaxone typically being infused over 30 minutes intravenous
41 and cefotaxime being given as a bolus. However, the committee agreed that this practice is
42 not necessary, as ceftriaxone can be given as bolus. Sometimes there may be a reaction (for
43 example, vomit reflex) if ceftriaxone is administered too quickly, but in the committee's
44 experience this is relatively rare, which was supported by a recent study (Patel 2021). The
45 committee agreed that ceftriaxone should be given as first-line treatment for Streptococcus
46 pneumoniae meningitis, unless contraindicated in which case cefotaxime can be considered.
47 The committee highlighted contraindications around pre-term babies less than 41 weeks

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

1    corrected gestational age and included a reference to these in the BNFC in the
2    recommendation in order to raise awareness.

3    The committee were aware that the previous NICE guideline on meningitis (NICE 2010)
4    recommended 14 days of intravenous ceftriaxone as first line treatment for Streptococcus
5    pneumoniae meningitis. However, the committee noted that the evidence reviewed showed
6    no important difference between 5 and 10 days of ceftriaxone therapy, although this study
7    was unlikely to have been adequately powered to be taken as definitive evidence of
8    equivalence. The committee acknowledged that practice has changed since the previous
9    NICE guideline, and that the previous recommendations were consensus rather than
10    evidence based and pre-dated the widespread use of cephalosporins. Based on their clinical
11    knowledge and experience, the committee agreed that most non-complicated cases would
12    be resolved in 10 days and extending to 14 days could lead to hospital overstay. The
13    committee were also aware that many authorities (for example, UK Joint Societies
14    guidelines, European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
15    guidelines, and Infectious Diseases Society of America clinical practice guidelines) have
16    changed their recommendations for Streptococcus pneumoniae meningitis to treatment
17    durations of 10 days, or 10 to 14 days. The committee recommended that people with
18    meningitis caused by Streptococcus pneumoniae should be treated for 10 days with
19    ceftriaxone (or cefotaxime if ceftriaxone contraindicated). The committee also agreed that
20    advice from an infection specialist (a microbiologist or infectious diseases specialist) should
21    be sought if people have not recovered after 10 days.

22    There was no evidence found on antibiotic use for Streptococcus pneumoniae meningitis in
23    people with a penicillin allergy, but the committee agreed it was important to make a
24    recommendation for this population. Based on their clinical knowledge and experience, the
25    committee agreed that cephalosporin-induced anaphylaxis is rare, and the risk-benefit
26    balance of a cephalosporin (relative to chloramphenicol as an alternative) is favourable in
27    most patients with non-anaphylactic penicillin allergy. Therefore, the committee agreed that
28    clinicians should seek information about the nature of the allergy and advice from an
29    infection specialist before making a treatment decision. The committee acknowledged that it
30    is important that treatment is not delayed; however, they agreed that information about the
31    nature of allergy is often readily available from the patient's family. The committee agreed
32    that a cephalosporin should still be considered if the nature of the allergic reaction they get is
33    non-anaphylactic or non- severe, in accordance with the first line treatment recommended
34    above. However, if the allergic reaction is anaphylactic or severe, alternatives to ceftriaxone
35    or cefotaxime will be needed. The committee discussed that chloramphenicol is commonly
36    used in the case of severe beta-lactam (penicillin, amoxicillin, or cephalosporin) allergy.
37    Based on clinical knowledge and experience, the committee recommended chloramphenicol
38    for people with Streptococcus pneumoniae meningitis and anaphylactic or severe penicillin
39    allergy.

40    The committee were aware that the previous NICE guideline on bacterial meningitis (NICE
41    2010) recommended to treat people who have travelled outside the UK with vancomycin (in
42    addition to the cephalosporin). However, they discussed that practice has changed since the
43    previous NICE guideline. The committee were aware that current practice is to use rifampicin
44    or linezolid in addition to a cephalosporin where the cephalosporin itself might be insufficient
45    due to resistance. However, the committee highlighted that there is no evidence to support
46    recommending them as it was out of scope of this review. Therefore, the committee
47    recommended that, clinicians should seek advice from an infection specialist if cephalosporin
48    resistance is suspected in people who have recently travelled abroad.

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

## Cost effectiveness and resource use

This review question was not prioritised for economic analysis and therefore the committee made a qualitative assessment of the likely cost-effectiveness of their recommendations. The committee considered that it would be cost-effective to recommend stopping intravenous ceftriaxone for Streptococcus pneumoniae meningitis after 10 days providing the person had clinically recovered. They reasoned that this reduction from previous NICE guidance (NICE 2010) could reduce unnecessary hospital inpatient stay. Using their clinical expertise and knowledge they reasoned that this would not lead to worse outcomes as most non-complicated cases would resolve within 10 days. They noted that the 14 days was not based on evidence and predated the wide use of cephalosporins. The committee believed therefore that their recommendation could lead to some cost savings for the NHS.

## Recommendations supported by this evidence review

This evidence review supports recommendations 1.6.4, 1.6.10 and 1.6.16. Other evidence supporting the recommendations 1.6.4 and 1.6.16 can be found in evidence reviews on antibiotic regimens for bacterial meningitis before or in the absence of identifying causative infecting organism (see evidence reviews D1 to D3) and for specific causative organisms (see evidence reviews E2 to E6).

1

# References – included studies

**Effectiveness**

**Molyneux 2011**

Molyneux, Elizabeth, Nizami, Shaikh Qamaruddin, Saha, Samir et al., 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet (London, England), 377(9780), 1837-45, 2011

**Economic**

No studies were identified which were applicable to this review question.

**Other**

**European Society of Clinical Microbiology and Infectious Diseases 2016**

van de Beek,D., Cabellos, C., Dzupova, O., Esposito, S., Klein, M., Kloek, A.T., Leib, S.L., Mourvillier, B., Ostergaard, C., Pagliano, P., Pfister, H.W., ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical microbiology and infection, 22, S37-S62, 2016

**Gbesemete 2019**

Gbesemete, D., Faust, S. (2019). Prescribing in infection: antibacterials. In. Barker, C., Turner, M., Sharland, M. (Eds.) Prescribing Medicines for Children: From drug development to practical administration, Pharmaceutical Press, London: UK

**Infectious Diseases Society of America 2017**

Tunkel, A.R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S.L., Scheld, W.M., van de Beek, D., Bleck, T.P., Garton, H.J., Zunt, J.R., 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clinical Infectious Diseases, 64(6), e34-e65, 2017

**Joint Formulary Committee 2022**

Joint Formulary Committee, British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Available at: http://www.medicinescomplete.com [Accessed 04/04/2022]

**NICE 2010**

National Institute for Health and Care Excellence, Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management. 2010. Available at: https://www.nice.org.uk/guidance/cg102 [Accessed 04/04/2022]

13

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

**Paediatric Formulary Committee 2022**

Paediatric Formulary Committee. BNF for Children (online). London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. Available at: http://www.medicinescomplete.com [Accessed 29/03/2022]

**Patel 2021**

Patel, S., Green. H., Gray, J., Rutter, M., Bevan, A., Hand, K., Jones, C. E., Faust, S. N. (2021). Evaluating Ceftriaxone 80 mg/kg Administration by Rapid Intravenous Infusion—A Clinical Service Evaluation. The Pediatric Infectious Disease Journal, 40(2), 128-129

**UK Joint Societies 2016**

McGill, F., Heyderman, R.S., Michael, B.D., Defres, S., Beeching, N.J., Borrow, R., Glennie, L., Gaillemin, O., Wyncoll, D., Kaczmarski, E., Nadel, S., The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. Journal of Infection, 72(4), 405-438, 2016

# 1 Appendices

## 2 Appendix A  Review protocols

**3 Review protocol for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis**
**4 caused by Streptococcus pneumoniae?**

**5 Table 3:   Review protocol**

| Field | Content |
| --- | --- |
| PROSPERO registration number | CRD42021276505 |
| Review title | Antibiotics for bacterial meningitis caused by Streptococcus pneumoniae |
| Review question | What antibiotic treatment regimens are effective in treating bacterial meningitis caused by Streptococcus pneumoniae? |
| Objective | This review aims to find out what is the optimal antibiotic treatment regimen in improving outcomes for people with bacterial meningitis caused by Streptococcus pneumoniae |
| Searches | The following databases will be searched:<br>• Cochrane Central Register of Controlled Trials (CENTRAL)<br>• Cochrane Database of Systematic Reviews (CDSR)<br>• Embase<br>• MEDLINE<br>Searches will be restricted by:<br>• Date limitations: 1980<br>• English language<br>• Human studies<br>The full search strategies for MEDLINE database will be published in the final review.<br>For each search, the principal database search strategy is quality assured by a second information scientist using an adaptation of the PRESS 2015 Guideline Evidence-Based Checklist. |

15

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

| Field | Content |
|---|---|
| Condition or domain being studied | Bacterial meningitis caused by Streptococcus pneumoniae |
| Population | Inclusion: All adults, young people, children and babies (excluding neonates defined as aged 28 days old and younger) with confirmed bacterial meningitis caused by Streptococcus pneumoniae<br><br>Exclusion:<br>People:<br>• with known immunodeficiency.<br>• who have brain tumours, pre-existing hydrocephalus, intracranial shunts, previous neurosurgical procedures, or known cranial or spinal anomalies that increase the risk of bacterial meningitis.<br>• with confirmed viral meningitis or viral encephalitis.<br>• with confirmed tuberculous meningitis.<br>• with confirmed fungal meningitis. |
| Intervention/Exposure/Test | Antibiotic agent of interest:<br>• Cefotaxime<br>• Ceftriaxone<br>• Chloramphenicol<br>• Ciprofloxacin<br>• Moxifloxacin<br>• Levofloxacin<br>• Benzylpencillin sodium<br>• Ampicillin<br>• Amoxicillin<br>• Meropenem<br>• Linezolid<br>• Daptomycin<br>• Co-trimoxazole |

| Field | Content |
|---|---|
| | • Rifampicin<br>• Vancomycin |
| Comparator/Reference standard/Confounding factors | **Stage 1 (all antibiotic agents of interest):**<br>• Antibiotic agent A (single or combination)* vs Antibiotic agent B (single or combination)*<br><br>* Rifampicin and vancomycin to be used in combination with other antibiotics not as monotherapy.<br><br>**Stage 2 (antibiotic agents identified during stage 1 as most effective/for use where there are contraindications)**<br>Comparisons:<br>1. Antibiotic agent A – Dose A vs Antibiotic agent A – Dose B<br>2. Antibiotic agent A – Duration of administration A vs Antibiotic agent A – Duration of administration B<br>3. Antibiotic agent A – Short infusion vs Antibiotic agent A – Extended infusion |
| Types of study to be included | Include published full-text papers:<br>• Systematic reviews of RCTs<br>• RCTs<br>• If insufficient RCTs: prospective cohort studies<br>• If insufficient prospective cohort studies: retrospective cohort studies<br>Non-randomised studies will be downgraded for risk of bias if they do not adequately adjust for the following covariates, but will not be excluded for this reason:<br>• Co-morbidity<br>• Severity of infection at presentation (including sepsis)<br><br>Exclude:<br>• Conference abstracts |

| Field | Content |
|---|---|
| Other exclusion criteria | Cohort studies from low income countries. |
| | Studies conducted prior to 1980 as currently used antibiotics were not in common usage prior to this date. |
| | Studies published not in English-language |
| Context | This guidance will fully update the following: Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102) |
| Primary outcomes (critical outcomes) | **Adults**<br>• All-cause mortality (measured up to 1 year after discharge)<br>• Any long-term neurological impairment (defined as any motor deficits, sensory deficits [excluding hearing impairment], cognitive deficits, or behavioural deficits; measured from discharge up to 1 year after discharge)<br>• Functional impairment (measured by any validated scale at any time point)<br><br>**Children and infants**<br>• All-cause mortality (measured up to 1 year after discharge)<br>• Any long-term neurological impairment (defined as any motor deficits, sensory deficits [excluding hearing impairment], cognitive deficits*, or behavioural deficits*; measured from discharge up to 1 year after discharge)<br>• Severe developmental delay (defined as score of >2 SD below normal on validated assessment scales, or MDI or PDI <70 on Bayleys assessment scale, or inability to assign a score due to cerebral palsy or severity of cognitive delay; measured at the oldest age reported unless there is substantially more data available at a younger age)<br><br>*For infants and children below school-age, cognitive and behavioural deficits will be assessed at school-age. |
| Secondary outcomes (important outcomes) | **Adults**<br>• Hearing impairment (defined as any level of hearing impairment; measured from discharge up to 1 year after discharge) |

| Field | Content |
|---|---|
| | • Serious intervention-related adverse effects leading to death, disability or prolonged hospitalisation or that are life threatening or otherwise considered medically significant<br><br>• CSF sterilisation (defined as treatment failure, time-to-sterilisation or delay).<br><br>• Intracranial collections as a complication (defined as abscess or empyema)<br><br>**Children and infants**<br><br>• Hearing impairment (defined as any level of hearing impairment; measured from discharge up to 1 year after discharge)<br><br>• Functional impairment (measured by any validated scale at any time point)<br><br>• Serious intervention-related adverse effects leading to death, disability or prolonged hospitalisation or that are life threatening or otherwise considered medically significant<br><br>• CSF sterilisation (defined as treatment failure, time to sterilisation or delay) |
| Data extraction (selection and coding) | All references identified by the searches and from other sources will be uploaded into STAR and de-duplicated. Titles and abstracts of the retrieved citations will be screened to identify studies that potentially meet the inclusion criteria outlined in the review protocol. Dual sifting will not be undertaken for this question. Full versions of the selected studies will be obtained for assessment. Studies that fail to meet the inclusion criteria once the full version has been checked will be excluded at this stage. Each study excluded after checking the full version will be listed, along with the reason for its exclusion. A standardised form will be used to extract data from studies. The following data will be extracted: study details (reference, country where study was carried out, type and dates), participant characteristics, inclusion and exclusion criteria, details of the interventions if relevant, setting and follow-up, relevant outcome data and source of funding. One reviewer will extract relevant data into a standardised form, and this will be quality assessed by a senior reviewer. |
| Risk of bias (quality) assessment | Quality assessment of individual studies will be performed using the following checklists:<br>• ROBIS tool for systematic reviews<br>• Cochrane RoB tool v.2 for RCTs and quasi-RCTs<br>• Cochrane ROBINS-I tool for non-randomised (clinical) controlled trials and cohort |

| Field | Content |
|---|---|
| | studies<br><br>The quality assessment will be performed by one reviewer and this will be quality assessed by a senior reviewer. |
| Strategy for data synthesis | Quantitative findings will be formally summarised in the review. Where multiple studies report on the same outcome for the same comparison, meta-analyses will be conducted using Cochrane Review Manager software. A fixed effect meta-analysis will be conducted and data will be presented as risk ratios if possible or odds ratios when required (for example if only available in this form in included studies) for dichotomous outcomes, and mean differences or standardised mean differences for continuous outcomes. Heterogeneity in the effect estimates of the individual studies will be assessed by visual inspection of the forest plots and consideration of the $I^2$ statistic.<br><br>Heterogeneity will be explored as appropriate using sensitivity analyses and pre-specified subgroup analyses. If heterogeneity cannot be explained through sensitivity analysis then a random effects model will be used for meta-analysis, or the data will not be pooled if the random effects model does not adequately address heterogeneity.<br><br>The confidence in the findings across all available evidence will be evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group: http://www.gradeworkinggroup.org/<br><br>**Minimally important differences:**<br><br>• All-cause mortality: statistical significance<br>• Serious intervention-related adverse effects: statistical significance<br>• CSF sterilization: statistical significance<br>• Intracranial collections: statistical significance<br>• Validated scales: Published MIDs where available; if not GRADE default MIDs<br>• All other outcomes: GRADE default MIDs |
| Analysis of sub-groups | Evidence will be stratified by:<br>**Stage 1**<br>Age: |

20

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

| Field | Content |
|---|---|
| | <ul><li>Younger Infants, older infants and children: >28 days to <18* years of age</li><li>Adults: ≥18* years of age</li></ul>**Stage 2**<br>Age:<ul><li>Younger Infants: >28 days to ≤3 months of age</li><li>Older infants and children: >3 months to <18* years of age</li><li>Adults: ≥18* years of age</li></ul>*There is variation in clinical practice regarding the treatment of 16 to 18 year olds. Therefore, we will be guided by cut-offs used in the evidence when determining if 16 to 18 year olds should be treated as adults or children.<br><br>Pneumococcal resistance (stated apriori in study):<ul><li>Beta-lactam resistance</li><li>No beta-lactam resistance</li></ul>Evidence will be subgrouped by the following only in the event that there is significant heterogeneity in outcomes:<br>Age:<ul><li>Young and middle aged adults</li><li>Older adults*</li></ul>*There is variation regarding the age at which adults should be considered older adults. Therefore, we will be guided by cut-offs used in the evidence when determining this threshold.<br>Where evidence is stratified or subgrouped the committee will consider on a case by case basis if separate recommendations should be made for distinct groups. Separate recommendations may be made where there is evidence of a differential effect of interventions in distinct groups. If there is a lack of evidence in one group, the committee will consider, based on their experience, whether it is reasonable to extrapolate and |

| Field | Content | | | |
|---|---|---|---|---|
| | assume the interventions will have similar effects in that group compared with others. | | | |
| Type and method of review | ☒ | Intervention | | |
| | ☐ | Diagnostic | | |
| | ☐ | Prognostic | | |
| | ☐ | Qualitative | | |
| | ☐ | Epidemiologic | | |
| | ☐ | Service Delivery | | |
| | ☐ | Other (please specify) | | |
| Language | English | | | |
| Country | England | | | |
| Anticipated or actual start date | 12/01/2021 | | | |
| Anticipated completion date | 07/12/2023 | | | |
| Stage of review at time of this submission | Review stage | | Started | Completed |
| | Preliminary searches | | ☑ | ☑ |
| | Piloting of the study selection process | | ☑ | ☑ |
| | Formal screening of search results against eligibility criteria | | ☑ | ☑ |
| | Data extraction | | ☑ | ☑ |
| | Risk of bias (quality) assessment | | ☑ | ☑ |
| | Data analysis | | ☑ | ☑ |
| Named contact | Named contact: National Guideline Alliance<br><br>Named contact e-mail: meningitis&meningococcal@nice.org.uk<br><br>Organisational affiliation of the review: National Institute for Health and Care Excellence | | | |

| Field | Content |
|---|---|
|  | (NICE) and National Guideline Alliance |
| Review team members | National Guideline Alliance |
| Funding sources/sponsor | This systematic review is being completed by the National Guideline Alliance which receives funding from NICE |
| Conflicts of interest | All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline. |
| Collaborators | Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual. Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10149. |
| Other registration details | None |
| Reference/URL for published protocol | https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=276505 |
| Dissemination plans | NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:<br><br>• notifying registered stakeholders of publication<br><br>• publicising the guideline through NICE's newsletter and alerts<br><br>• issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE. |
| Keywords | Bacterial meningitis, antibiotic, anti-bacterial, mortality, impairments |
| Details of existing review of same topic by same authors | None |

| Field | Content | |
|---|---|---|
| Current review status | ☐ | Ongoing |
| | ☒ | Completed but not published |
| | ☐ | Completed and published |
| | ☐ | Completed, published and being updated |
| | ☐ | Discontinued |
| Additional information | None | |
| Details of final publication | www.nice.org.uk | |

1 *CDSR: Cochrane Database of Systematic Reviews; CENTRAL: Cochrane Central Register of Controlled Trials; CSF: cerebrospinal fluid; GRADE: Grading of*
2 *Recommendations Assessment, Development and Evaluation; MDI: mental development index; MEDLINE: Medical Literature Analysis and Retrieval System Online; MID:*
3 *minimally important difference; NICE: National Institute for Health and Care Excellence; PDI: psychomotor development index;  PRESS: Peer Review of Electronic Search*
4 *Strategies; RCT: randomised controlled trial; RoB: risk of bias; ROBINS-I: risk of bias in non-randomised studies – of interventions; ROBIS: risk of bias in systematic reviews;*
5 *SD: standard deviation*
6

24

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

# 1 Appendix B Literature search strategies

**2 Literature search strategies for review question: What antibiotic treatment**
**3 regimens are effective in treating bacterial meningitis caused Streptococcus**
**4 pneumoniae?**
5

6 This was a combined search to cover both this review and D1, D2, D3, E2, E3, E4, E5, E6
7 and F1 on antibiotic regimens for bacterial meningitis (before or in the absence of identifying
8 causative infecting organism and for specific causative organisms) and meningococcal
9 disease.
10
**11 Clinical Search**
12
**13 Database(s): Medline & Embase (Multifile) – OVID interface**
**14 Embase Classic+Embase** 1947 to 2022 November 09, **Ovid MEDLINE(R) and Epub**
**15 Ahead of Print, In-Process & Other Non-Indexed Citations and Daily** 1946 to November
16 09, 2022
17 Date of last search: 10 November 2022
18 *Multifile database codes: emczd = Embase Classic+Embase; ppez = MEDLINE(R) and Epub Ahead of*
19 *Print, In-Process & Other Non-Indexed Citations and Daily*

| # | Searches |
|---|---|
| 1 | Meningitis/ or Meningitis, Bacterial/ or Meningitis, Escherichia Coli/ or Meningitis, Haemophilus/ or Meningitis, Listeria/ or Meningitis, Meningococcal/ or Meningitis, Pneumococcal/ or Meningoencephalitis/ |
| 2 | 1 use ppez |
| 3 | meningitis/ or bacterial meningitis/ or haemophilus meningitis/ or hemophilus influenzae meningitis/ or listeria meningitis/ or meningococcal meningitis/ or pneumococcal meningitis/ or meningoencephalitis/ |
| 4 | 3 use emczd |
| 5 | ((bacter* or infect*) adj3 (meningit* or meninges* or leptomeninges* or subarachnoid space?)).ti,ab. |
| 6 | (meningit* adj3 (e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon* or septic* or sepsis* or bacter?emi?)).ti,ab. |
| 7 | ((e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon*) adj3 (septic* or sepsis* or bacter?emi?)).ti,ab. |
| 8 | (meningit* or mening?encephalitis*).ti,ab. |
| 9 | exp Neisseria meningitidis/ use ppez |
| 10 | neisseria meningitidis/ use emczd |
| 11 | (Neisseria* mening* or n mening*).ti,ab. |
| 12 | or/2,4-11 |
| 13 | Meningococcal Infections/ use ppez |
| 14 | meningococcosis/ or meningococcemia/ |
| 15 | 14 use emczd |
| 16 | (meningococc* adj3 (sepsis* or septic* or toxic* or endotoxic* or disease? or infection?)).ti,ab. |
| 17 | (meningococcus* or meningococci* or meningococc?emi?).ti,ab. |
| 18 | or/13,15-17 |
| 19 | exp Anti-Bacterial Agents/ or exp Penicillins/ or exp Cephalosporins/ or exp Cefotaxime/ or exp Amoxicillin/ or exp Ampicillin/ |
| 20 | 19 use ppez |
| 21 | exp antibiotic agent/ or antibiotic therapy/ or exp penicillin derivative/ or exp cephalosporin derivative/ |
| 22 | 21 use emczd |
| 23 | (anti?biotic* or anti?bacterial* or anti?biotherap*).ti,ab. |
| 24 | (empiric* adj2 (therap* or treatment*)).ti,ab. |
| 25 | (abbocillin or adimicin or alcomicin or alpen or amblosin or amcill or amfipen or aminobenzylpenicillin* or aminoglycosid* or amox?cillin* or amoxil* or ampicillin* or ancef or anticepim or apogen or axepim* or ayercillin or azithrom?cin* or benzo?penicillin* or benzyl?penicillin* or bicillin or binotal or biomox or bmy 28142 or bmy?28142 or bristagen or bristamox or carbapenem* or cedax or ceftazidim* or cefatriaxon* or cefepim* or cefixim* or cefizox or cefobid* or cefotan or cefotaxim* or ceftaroline* or ceftin or ceftolozane* or ceftriaxon* or ceftriazon* or cefuroxim* or cefzil or cepazin* or cephalosporin* or cephotaxim* or cephuroxim* or cepim?x or chloramphenicol* or ciprofloxacin* or claforan or clamoxyl or clarithromycin* or clindamycin* or colistin* or compocillin or cosmopen or cotrimoxazol* or co trimoxazol* or crysticillin or delafloxacin* or deripen or dexamethasone or diatracin or doktacillin or duricef or elobact or erythromycin* or flucloxacillin* or fluoroquinolon* or fosfomycin* or gelacillin or gentam?cin* or gent?mycin* or gentamyl* or gentamytrex or gentaplus or gentarad or gentaso* or gentasporin or gentatrim or gent?cin* or gent?cyn* |

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

| # | Searches |
|---|---|
| | or geocillin* or geomycin* or glycopeptid* or guicitrin* or hexam?cin* or hiconcil or histocillin or ibiamox or imacillin or jenamicin or kefurox or kefzol or klaforan or lendacin or levofloxacin* or linezolid* or longacef or longaceph or lyphocin or macrolide* or mandol or maxcef or maxipim* or mefoxin or megacillin or meropen* or miram?cin* or monocid or moxacin or moxifloxacin* or ofloxacin* or oftagen* or omnipen or optigen* or pefloxacin* or penbritin* or penbrock or penicillin? or penicline or pentids or pentrex or pentrexl or pentrexyl or permapen or pfizerpen or polycillin or polymox or polymyxin*or primafen or principen or quinolon* or refobacin* or ribom?cin* or rifampicin or rifampin* or rocefalin or rocefin or rocephin* or roscillin or rufloxacin* or sagestam* or spectrobid or sulm?cin* or supen or tazobactam* or terram?cin* or tetracycline* or tobramycin* or totacillin or totapen or trimox or u?gencin* or ukapen or ultrabion or vamysin or vancam* or vanccostacin or vancin or vancom* or vancomycin* or vankom* or velosef or vetramox* or viccillin or voncon* or wycillin or zimox or zinacef or zin?at).mp. |
| 26 | or/20,22-25 |
| 27 | (12 or 18) and 26 |
| 28 | (controlled clinical trial or pragmatic clinical trial or randomized controlled trial).pt. or drug therapy.fs. or (groups or placebo or randomi#ed or randomly or trial).ab. |
| 29 | crossover procedure/ or double blind procedure/ or randomized controlled trial/ or single blind procedure/ or (assign* or allocat* or crossover* or cross over* or ((doubl* or singl*) adj blind*) or factorial* or placebo* or random* or volunteer*).ti,ab. |
| 30 | meta-analysis/ |
| 31 | meta-analysis as topic/ |
| 32 | systematic review/ |
| 33 | meta-analysis/ |
| 34 | (meta analy* or metanaly* or metaanaly*).ti,ab. |
| 35 | ((systematic or evidence) adj2 (review* or overview*)).ti,ab. |
| 36 | ((systematic* or evidence*) adj2 (review* or overview*)).ti,ab. |
| 37 | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. |
| 38 | (search strategy or search criteria or systematic search or study selection or data extraction).ab. |
| 39 | (search* adj4 literature).ab. |
| 40 | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 41 | cochrane.jw. |
| 42 | ((pool* or combined) adj2 (data or trials or studies or results)).ab. |
| 43 | letter/ |
| 44 | editorial/ |
| 45 | news/ |
| 46 | exp historical article/ |
| 47 | Anecdotes as Topic/ |
| 48 | comment/ |
| 49 | case report/ |
| 50 | (letter or comment*).ti. |
| 51 | 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 |
| 52 | randomized controlled trial/ or random*.ti,ab. |
| 53 | 51 not 52 |
| 54 | animals/ not humans/ |
| 55 | exp Animals, Laboratory/ |
| 56 | exp Animal Experimentation/ |
| 57 | exp Models, Animal/ |
| 58 | exp Rodentia/ |
| 59 | (rat or rats or mouse or mice).ti. |
| 60 | 53 or 54 or 55 or 56 or 57 or 58 or 59 |
| 61 | letter.pt. or letter/ |
| 62 | note.pt. |
| 63 | editorial.pt. |
| 64 | case report/ or case study/ |
| 65 | (letter or comment*).ti. |
| 66 | 61 or 62 or 63 or 64 or 65 |
| 67 | randomized controlled trial/ or random*.ti,ab. |
| 68 | 66 not 67 |
| 69 | animal/ not human/ |
| 70 | nonhuman/ |
| 71 | exp Animal Experiment/ |
| 72 | exp Experimental Animal/ |
| 73 | animal model/ |
| 74 | exp Rodent/ |
| 75 | (rat or rats or mouse or mice).ti. |
| 76 | 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 |
| 77 | 60 use ppez |
| 78 | 76 use emczd |
| 79 | 77 or 78 |

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

| # | Searches |
|---|---|
| 80 | 28 use ppez |
| 81 | 29 use emczd |
| 82 | 80 or 81 |
| 83 | (or/30-31,34,36-41) use ppez |
| 84 | (or/32-35,37-42) use emczd |
| 85 | 83 or 84 |
| 86 | 27 not 79 |
| 87 | limit 86 to English language |
| 88 | limit 87 to yr="1980 -Current" |
| 89 | limit 88 to (conference abstract or conference paper or conference review or conference proceeding) [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] |
| 90 | 89 use emczd |
| 91 | 88 not 90 |
| 92 | 82 or 85 |
| 93 | 91 and 92 [SR/RCT data] |
| 94 | 91 not 93 [Non-RCT data] |

1

2 **Database(s): Cochrane Library – Wiley interface**

3 **Cochrane Database of Systematic Reviews**, Issue 11 of 12, November 2022, **Cochrane**

4 **Central Register of Controlled Trials**, Issue 11 of 12, November 2022

5 Date of last search: 10 November 2022

| # | Searches |
|---|---|
| #1 | MeSH descriptor: [Meningitis] this term only |
| #2 | MeSH descriptor: [Meningitis, Bacterial] this term only |
| #3 | MeSH descriptor: [Meningitis, Escherichia coli] this term only |
| #4 | MeSH descriptor: [Meningitis, Haemophilus] this term only |
| #5 | MeSH descriptor: [Meningitis, Listeria] this term only |
| #6 | MeSH descriptor: [Meningitis, Meningococcal] this term only |
| #7 | MeSH descriptor: [Meningitis, Pneumococcal] this term only |
| #8 | MeSH descriptor: [Meningoencephalitis] this term only |
| #9 | MeSH descriptor: [Neisseria meningitidis] explode all trees |
| #10 | ((bacter* or infect*) near/3 (mening* or leptomening* or subarachnoid space*)):ti,ab,kw |
| #11 | (("e coli" or "escherichia coli" or haemophilus or hemophilus or hib or (h next influenz*) or listeria* or pneumococc* or (gram next negativ* next bacill*) or streptococc* or GBS or (s next pneumon*)) near/3 (septic* or sepsis* or bacteraemi* or bacteremi* or infect*)):ti,ab,kw |
| #12 | (meningit* or mening?encephalitis* or (mening* next encephalitis*)).:ti,ab,kw |
| #13 | ((neisseria* next mening*) or (n next mening*)):ti,ab,kw |
| #14 | MeSH descriptor: [Meningococcal Infections] this term only |
| #15 | meningococc*:ti,ab,kw |
| #16 | {or #1-#15} |
| #17 | MeSH descriptor: [Anti-Bacterial Agents] explode all trees |
| #18 | ((antibiotic* or antibacterial* or antibiotherap* or "anti biotic*" or "anti bacterial*" or "anti biotherap*")):ti,ab,kw |
| #19 | ((empiric* near/2 (therap* or treatment*))):ti,ab,kw |
| #20 | ((abbocillin or adimicin or alcomicin or alpen or amblosin or amcill or amfipen or aminobenzylpenicillin* or aminoglycosid* or amox?cillin* or amoxil* or ampicillin* or ancef or anticepim or apogen or axepim* or ayercillin or azithrom?cin* or benzo?penicillin* or benzyl?penicillin* or bicillin or binotal or biomox or bmy 28142 or bmy?28142 or bristagen or bristamox or carbapenem* or cedax or ceftazidim* or cefatriaxon* or cefepim* or cefixim* or cefizox or cefobid* or cefotan or cefotaxim* or ceftaroline* or ceftin or ceftolozane* or ceftriaxon* or ceftriazon* or cefuroxim* or cefzil or cepazin* or cephalosporin* or cephotaxim* or cephuroxim* or cepim?x or chloramphenicol* or ciprofloxacin* or claforan or clamoxyl or clarithromycin* or clindamycin* or colistin* or compocillin or cosmopen or cotrimoxazol* or co trimoxazol* or crysticillin or delafloxacin* or deripen or dexamethasone or diatracin or doktacillin or duricef or elobact or erythromycin* or flucloxacillin* or fluoroquinolon* or fosfomycin* or gelacillin or gentam?cin* or gent?mycin* or gentamyl* or gentamytrex or gentaplus or gentarad or gentaso* or gentasporin or gentatrim or gent?cin* or gent?cyn* or geocillin* or geomycin* or glycopeptid* or guicitrin* or hexam?cin* or hiconcil or histocillin or ibiamox or imacillin or jenamicin or kefurox or kefzol or klaforan or lendacin or levofloxacin* or linezolid* or longacef or longaceph or lyphocin or macrolide* or mandol or maxcef or maxipim* or mefoxin or megacillin or meropen* or miram?cin* or monocid or moxacin or moxifloxacin* or ofloxacin* or oftagen* or omnipen or optigen* or pefloxacin* or penbritin* or penbrock or penicillin? or penicline or pentids or pentrex or pentrexl or pentrexyl or permapen or pfizerpen or polycillin or polymox or polymyxin*or primafen or principen or quinolon* or refobacin* or ribom?cin* or rifampicin or rifampin* or rocefalin or rocefin or rocephin* or roscillin or rufloxacin* or sagestam* or spectrobid or sulm?cin* or supen or tazobactam* or terram?cin* or tetracycline* or tobramycin* or totacillin or totapen or trimox or u?gencin* or ukapen or ultrabion or vamysin or vancam* or vanccostacin or vancin or vancom* or vancomycin* or vankom* or velosef or vetramox* or viccillin or voncon* or wycillin or zimox or zinacef or zin?at)):ti,ab,kw |
| #21 | {or #17-#20} |
| #22 | #16 and #21 |
| #23 | "conference":pt or (clinicaltrials or trialsearch):so |
| #24 | #22 not #23 |

27

1

2 **Database(s): Database of Abstracts of Reviews of Effects (DARE); HTA Database –**
3 **CRD interface**

4 Date of last search: 12 February 2021

| # | Searches |
|---|---|
| 1 | MeSH DESCRIPTOR meningitis IN DARE,HTA |
| 2 | MeSH DESCRIPTOR meningitis, bacterial IN DARE,HTA |
| 3 | MeSH DESCRIPTOR Meningitis, Escherichia coli IN DARE,HTA |
| 4 | MeSH DESCRIPTOR Meningitis, Haemophilus IN DARE,HTA |
| 5 | MeSH DESCRIPTOR Meningitis, Listeria IN DARE,HTA |
| 6 | MeSH DESCRIPTOR Meningitis, Meningococcal IN DARE,HTA |
| 7 | MeSH DESCRIPTOR Meningitis, Pneumococcal IN DARE,HTA |
| 8 | MeSH DESCRIPTOR Meningoencephalitis IN DARE,HTA |
| 9 | MeSH DESCRIPTOR Meningococcal infections IN DARE,HTA |
| 10 | (((((bacter* or infect*) NEAR3 (meningit* or meninges* or leptomeninges* or "subarachnoid space*"))))) IN DARE, HTA |
| 11 | (meningit*) IN DARE, HTA |
| 12 | ((((meningencephalitis* or meningoencephalitis*)))) IN DARE, HTA |
| 13 | ((((meningococc* NEAR3 (sepsis* or septic* or toxic* or endotoxic* or disease or diseases or infection or infections))))) IN DARE, HTA |
| 14 | ((((meningococcus* or meningococci* or meningococcaemia* or meningococcemia*)))) IN DARE, HTA |
| 15 | ((Neisseria* NEAR1 mening*)) IN DARE, HTA |
| 16 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 |
| 17 | MeSH DESCRIPTOR Anti-Bacterial Agents EXPLODE ALL TREES IN DARE,HTA |
| 18 | MeSH DESCRIPTOR Penicillins EXPLODE ALL TREES IN DARE,HTA |
| 19 | MeSH DESCRIPTOR Cephalosporins EXPLODE ALL TREES IN DARE,HTA |
| 20 | MeSH DESCRIPTOR Cefotaxime EXPLODE ALL TREES IN DARE,HTA |
| 21 | MeSH DESCRIPTOR Amoxicillin EXPLODE ALL TREES IN DARE,HTA |
| 22 | MeSH DESCRIPTOR Ampicillin EXPLODE ALL TREES IN DARE,HTA |
| 23 | (((antibiotic* or antibacterial* or antibiotherap* or anti-biotic* or anti-bacterial* or anti-biotherap* or "anti biotic*" or "anti bacterial*" or "anti biotherap*"))) IN DARE, HTA |
| 24 | (((empiric* NEAR2 (therap* or treatment*)))) IN DARE, HTA |
| 25 | (((abbbocillin or adimicin or alcomicin or alpen or amblosin or amcill or amfipen or aminobenzylpenicillin or amox?cillin or amoxil* or ampicillin or ancef or anticepim or apogen or axepim* or ayercillin or benzo?penicillin* or benzyl?penicillin* or bicillin or binotal or biomox or bmy 28142 or bmy-28142 or bmy28142 or bristagen or bristamox or cedax or cefatriaxon* or cefepim* or cefixim* or cefizox or cefobid* or cefotan or cefotaxim* or ceftin or ceftriaxon* or ceftriazon* or cefuroxim* or cefzil or cepazin* or cephotaxim* or cephuroxim* or cepim?x or chloramphenicol or claforan or clamoxyl or compocillin or cosmopen or cotrimoxazol* or co trimoxazol* or co-trimoxazol or crysticillin or deripen or dexamethasone or diatracin or doktacillin or duricef or elobact or gelacillin or gentam?cin* or gent?mycin* or gentamyl* or gentamytrex or gentaplus or gentarad or gentaso* or gentasporin or gentatrim or gent?cin* or gent?cyn* or geocillin* or geomycin* or guicitrin* or hexam?cin* or hiconcil or histocillin or ibiamox or imacillin or jenamicin or kefurox or kefzol or klaforan or lendacin or longacef or longaceph or lyphocin or mandol or maxcef or maxipim* or mefoxin or megacillin or meropen* or miram?cin* or monocid or moxacin or oftagen* or omnipen or optigen* or penbritin* or penbrock or penicillin? or penicline or pentids or pentrex or pentrexl or pentrexyl or permapen or pfizerpen or polycillin or polymox or primafen or principen or refobacin* or ribom?cin* or rifampicin or rocefalin or rocefin or rocephin* or roscillin or sagestam* or spectrobid or sulm?cin* or supen or terram?cin* or totacillin or totapen or trimox or u?gencin* or ukapen or ultrabion or vamysin or vancam* or vanccostacin or vancin or vancom* or vancomycin or vankom* or velosef or vetramox* or viccillin or voncon* or wycillin or zimox or zinacef or zin?at))) IN DARE, HTA |
| 26 | #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 |
| 27 | #16 AND #26 |

5

1

## Economic Search

One global search was conducted for economic evidence across the guideline.

**Database(s): NHS Economic Evaluation Database (NHS EED), HTA Database – CRD interface**

Date of last search: 11 March 2021

| # | Searches |
|---|----------|
| 1 | MeSH DESCRIPTOR meningitis IN NHSEED,HTA |
| 2 | MeSH DESCRIPTOR Meningitis, Bacterial IN NHSEED,HTA |
| 3 | MeSH DESCRIPTOR Meningitis, Escherichia coli IN NHSEED,HTA |
| 4 | MeSH DESCRIPTOR Meningitis, Haemophilus EXPLODE ALL TREES IN NHSEED,HTA |
| 5 | MeSH DESCRIPTOR Meningitis, Listeria IN NHSEED,HTA |
| 6 | MeSH DESCRIPTOR Meningitis, Meningococcal IN NHSEED,HTA |
| 7 | MeSH DESCRIPTOR Meningitis, Pneumococcal IN NHSEED,HTA |
| 8 | MeSH DESCRIPTOR Meningoencephalitis IN NHSEED,HTA |
| 9 | (((bacter* or infect*) NEAR3 (meningit* or meninges* or leptomeninges* or subarachnoid space*))) IN NHSEED, HTA |
| 10 | ((meningit* NEAR3 (e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon* or septic* or sepsis* or bacter?emi?))) IN NHSEED, HTA |
| 11 | (((e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon*) NEAR3 (septic* or sepsis* or bacter?emi?))) IN NHSEED, HTA |
| 12 | ((meningencephalitis* or meningoencephalitis* or meningit*)) IN NHSEED, HTA |
| 13 | MeSH DESCRIPTOR Meningococcal Infections IN NHSEED,HTA |
| 14 | MeSH DESCRIPTOR Neisseria meningitidis EXPLODE ALL TREES IN NHSEED,HTA |
| 15 | ((meningococc* NEAR3 (sepsis* or septic* or toxic* or endotoxic* or disease* or infection*))) IN NHSEED, HTA |
| 16 | ((meningococcus* or meningococci* or meningococcaemia* or meningococcemia*)) IN NHSEED, HTA |
| 17 | ((Neisseria* NEXT mening*)) IN NHSEED, HTA |
| 18 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 |

**Database(s): Medline & Embase (Multifile) – OVID interface**

**Embase Classic+Embase** 1947 to 2022 November 09, **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily** 1946 to November 09, 2022

Date of last search: 10 November 2022

*Multifile database codes: emczd = Embase Classic+Embase; ppez= MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily*

| # | Searches |
|---|----------|
| 1 | Meningitis/ or Meningitis, Bacterial/ or Meningitis, Escherichia Coli/ or Meningitis, Haemophilus/ or Meningitis, Listeria/ or Meningitis, Meningococcal/ or Meningitis, Pneumococcal/ or Meningoencephalitis/ |
| 2 | 1 use ppez |
| 3 | meningitis/ or bacterial meningitis/ or haemophilus meningitis/ or listeria meningitis/ or pneumococcal meningitis/ or meningoencephalitis/ |
| 4 | 3 use emczd |
| 5 | ((bacter* or infect*) adj3 (meningit* or meninges* or leptomeninges* or subarachnoid space?)).ti,ab. |
| 6 | (meningit* adj3 (e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon* or septic* or sepsis* or bacter?emi?)).ti,ab. |
| 7 | ((e coli or escherichia coli or h?emophilus or hib or h?emophilus influenz* or h influenz* or listeria* or meningococc* or pneumococc* or gram-negativ* bacill* or gram negativ* bacill* or streptococc* or group B streptococc* or GBS or streptococcus pneumon* or s pneumon*) adj3 (septic* or sepsis* or bacter?emi?)).ti,ab. |
| 8 | (mening?encephalitis* or meningit*).ti,ab. |
| 9 | or/2,4-8 |
| 10 | Meningococcal Infections/ or exp Neisseria meningitidis/ |
| 11 | 10 use ppez |
| 12 | Meningococcosis/ or Meningococcemia/ or Neisseria Meningitidis/ |
| 13 | 12 use emczd |
| 14 | (meningococc* adj3 (sepsis* or septic* or toxic* or endotoxic* or disease? or infection?)).ti,ab. |
| 15 | (meningococcus* or meningococci* or meningococc?emi?).ti,ab. |
| 16 | (Neisseria* mening* or n mening*).ti,ab. |

| # | Searches |
|---|---|
| 17 | or/11,13-16 |
| 18 | Economics/ use ppez |
| 19 | Value of life/ use ppez |
| 20 | exp "Costs and Cost Analysis"/ use ppez |
| 21 | exp Economics, Hospital/ use ppez |
| 22 | exp Economics, Medical/ use ppez |
| 23 | Economics, Nursing/ use ppez |
| 24 | Economics, Pharmaceutical/ use ppez |
| 25 | exp "Fees and Charges"/ use ppez |
| 26 | exp Budgets/ use ppez |
| 27 | health economics/ use emczd |
| 28 | exp economic evaluation/ use emczd |
| 29 | exp health care cost/ use emczd |
| 30 | exp fee/ use emczd |
| 31 | budget/ use emczd |
| 32 | funding/ use emczd |
| 33 | budget*.ti,ab. |
| 34 | cost*.ti. |
| 35 | (economic* or pharmaco?economic*).ti. |
| 36 | (price* or pricing*).ti,ab. |
| 37 | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 38 | (financ* or fee or fees).ti,ab. |
| 39 | (value adj2 (money or monetary)).ti,ab. |
| 40 | or/18-39 |
| 41 | Quality-Adjusted Life Years/ use ppez |
| 42 | Sickness Impact Profile/ |
| 43 | quality adjusted life year/ use emczd |
| 44 | "quality of life index"/ use emczd |
| 45 | (quality adjusted or quality adjusted life year*).tw. |
| 46 | (qaly* or qal or qald* or qale* or qtime* or qwb* or daly).tw. |
| 47 | (illness state* or health state*).tw. |
| 48 | (hui or hui2 or hui3).tw. |
| 49 | (multiattibute* or multi attribute*).tw. |
| 50 | (utilit* adj3 (score*1 or valu* or health* or cost* or measur* or disease* or mean or gain or gains or index*)).tw. |
| 51 | utilities.tw. |
| 52 | (eq-5d* or eq5d* or eq-5* or eq5* or euroqual* or euro qual* or euroqual 5d* or euro qual 5d* or euro qol* or euroqol*or euro quol* or euroquol* or euro quol5d* or euroquol5d* or eur qol* or eurqol* or eur qol5d* or eurqol5d* or eur?qul* or eur?qul5d* or euro* quality of life or european qol).tw. |
| 53 | (euro* adj3 (5 d* or 5d* or 5 dimension* or 5dimension* or 5 domain* or 5domain*)).tw. |
| 54 | (sf36 or sf 36 or sf thirty six or sf thirtysix).tw. |
| 55 | (time trade off*1 or time tradeoff*1 or tto or timetradeoff*1).tw. |
| 56 | Quality of Life/ and ((quality of life or qol) adj (score*1 or measure*1)).tw. |
| 57 | Quality of Life/ and ec.fs. |
| 58 | Quality of Life/ and (health adj3 status).tw. |
| 59 | (quality of life or qol).tw. and Cost-Benefit Analysis/ use ppez |
| 60 | (quality of life or qol).tw. and cost benefit analysis/ use emczd |
| 61 | ((qol or hrqol or quality of life).tw. or *quality of life/) and ((qol or hrqol* or quality of life) adj2 (increas* or decreas* or improv* or declin* or reduc* or high* or low* or effect or effects or worse or score or scores or change*1 or impact*1 or impacted or deteriorat*)).ab. |
| 62 | Cost-Benefit Analysis/ use ppez and cost-effectiveness ratio*.tw. and (cost-effectiveness ratio* and (perspective* or life expectanc*)).tw. |
| 63 | cost benefit analysis/ use emczd and cost-effectiveness ratio*.tw. and (cost-effectiveness ratio* and (perspective* or life expectanc*)).tw. |
| 64 | *quality of life/ and (quality of life or qol).ti. |
| 65 | quality of life/ and ((quality of life or qol) adj3 (improv* or chang*)).tw. |
| 66 | quality of life/ and health-related quality of life.tw. |
| 67 | Models, Economic/ use ppez |
| 68 | economic model/ use emczd |
| 69 | care-related quality of life.tw,kw. |
| 70 | ((capability$ or capability-based$) adj (measure$ or index or instrument$)).tw,kw. |
| 71 | social care outcome$.tw,kw. |
| 72 | (social care and (utility or utilities)).tw,kw. |
| 73 | or/41-72 |
| 74 | (9 or 17) and 40 |
| 75 | (9 or 17) and 73 |
| 76 | letter/ |
| 77 | editorial/ |
| 78 | news/ |

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

| # | Searches |
|---|----------|
| 79 | exp historical article/ |
| 80 | Anecdotes as Topic/ |
| 81 | comment/ |
| 82 | case report/ |
| 83 | (letter or comment*).ti. |
| 84 | 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 |
| 85 | randomized controlled trial/ or random*.ti,ab. |
| 86 | 84 not 85 |
| 87 | animals/ not humans/ |
| 88 | exp Animals, Laboratory/ |
| 89 | exp Animal Experimentation/ |
| 90 | exp Models, Animal/ |
| 91 | exp Rodentia/ |
| 92 | (rat or rats or mouse or mice).ti. |
| 93 | 86 or 87 or 88 or 89 or 90 or 91 or 92 |
| 94 | letter.pt. or letter/ |
| 95 | note.pt. |
| 96 | editorial.pt. |
| 97 | case report/ or case study/ |
| 98 | (letter or comment*).ti. |
| 99 | 94 or 95 or 96 or 97 or 98 |
| 100 | randomized controlled trial/ or random*.ti,ab. |
| 101 | 99 not 100 |
| 102 | animal/ not human/ |
| 103 | nonhuman/ |
| 104 | exp Animal Experiment/ |
| 105 | exp Experimental Animal/ |
| 106 | animal model/ |
| 107 | exp Rodent/ |
| 108 | (rat or rats or mouse or mice).ti. |
| 109 | 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 |
| 110 | 93 use ppez |
| 111 | 109 use emczd |
| 112 | 110 or 111 |
| 113 | 74 not 112 |
| 114 | limit 113 to English language |
| 115 | 75 not 112 |
| 116 | limit 115 to English language |
| 117 | 114 or 116 |

1

2

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

# 1    Appendix C  Effectiveness evidence study selection

2    **Study selection for: What antibiotic treatment regimens are effective in treating**
3    **bacterial meningitis caused by Streptococcus pneumoniae?**

4    **Figure 1: Study selection flow chart**



5

6

7

8

9

# 1 Appendix D Evidence tables

2 **Evidence tables for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis caused**
3 **by Streptococcus pneumoniae?**

4 **Table 4: Evidence tables – effectiveness evidence**

5 **Molyneux, 2011**

| | |
|---|---|
| **Bibliographic Reference** | Molyneux, Elizabeth; Nizami, Shaikh Qamaruddin; Saha, Samir; Huu, Khanh Truong; Azam, Matloob; Bhutta, Zulfiqar Ahmad; Zaki, Ramadan; Weber, Martin Willi; Qazi, Shamim Ahmad; Group, C. S. F. Study; 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study; Lancet (London, England); 2011; vol. 377 (no. 9780); 1837-45 |

6

7 **Study details**

| | |
|---|---|
| **Country/ies where study was carried out** | Bangladesh, Egypt, Malawi, Pakistan, and Vietnam |
| **Study type** | Randomised controlled trial (RCT) |
| **Study dates** | September 2001 - December 2006 |
| **Inclusion criteria** | Children aged 2 months to 12 years with bacterial meningitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Neisseria meningitidis who were alive on day 5 after the start of treatment and clinically stable or improving. Meningitis caused by study organisms was defined as positive CSF culture or latex agglutination, or positive blood culture plus >10 white blood cells per mL of CSF, or >100 white blood cells per mL of CSF with >50% granulocytes plus CSF glucose <1.66 mml/L or <50% of blood glucose, or >100 white blood cells per mL of CSF with 75% polymorphonuclear leukocytes. |
| **Exclusion criteria** | Exclusion criteria at enrolment: Age ≤2 months, body weight ≤3 kg, pre-existing neurosurgical conditions, cerebral palsy, seizure disorders, degenerative neurological conditions, skull fractures, active viral infections, known immunodeficiency, symptomatic AIDS, known hypersensitivity reaction to cephalosporins, cyanotic congenital heart |

| | |
|---|---|
| | disease, inaccessibility for follow-up, children treated with any parenteral antibiotics for 24 h before admission, and children randomly assigned on more than one occasion in this study<br><br>Exclusion criteria for random assignment at day 5: Criteria listed above, ceftriaxone-resistant bacteria, serious adverse reactions to the drug given, presence of or growth of bacteria from cerebrospinal fluid taken 48 to 72 h after admission, pyogenic brain abscess, intracranial suppurative thrombophlebitis, subdural empyema, presence of another infection during admission that needed another injectable antibiotic, and meningitis caused by any bacteria other than Haemophilus influenzae, Streptococcus pneumoniae, or Neisseria meningitidis. |
| **Patient characteristics** | Streptococcus pneumoniae n=335 (study also included bacterial meningitis with other causes (n=669) but these were not of interest for the current review); 5-day ceftriaxone therapy: 154; 10-day ceftriaxone therapy: 181<br><br>Age* (months in mean; SD in parentheses): 38.2 (42)<br><br>Sex*: male: 565 (56%); female: 439 (44%)<br><br>Etiology*: Haemophilus influenzae: 266 (27%); Streptococcus pneumoniae: 335 (33%); Neisseria meningitidis: 73 (7%); unknown: 330 (33%)<br><br>Children infected with HIV* **: 117 (12%)<br><br>*Reported for whole study, not based on causative organism<br><br>**Although HIV is listed as an exclusion criteria in the protocol, the evidence was not considered indirect as those with HIV accounted for <25% of the population |
| **Intervention(s)/control** | 5-day ceftriaxone therapy: Intravenous ceftriaxone 80-100 mg/kg once daily for 5 days followed by placebo for 5 days<br><br>10-day ceftriaxone therapy: Intravenous ceftriaxone 80-100 mg/kg once daily for 10 days |
| **Duration of follow-up** | Daily during hospitalisation, at discharge on day 10, and on day 40 and day 190 after enrolment |
| **Sources of funding** | Industry funded |

| Sample size | N=1004*<br><br>*Reported for whole study, not based on causative organism |
| --- | --- |
| Other information | 437 (43.5%) children (5-day ceftriaxone therapy: 209; 10-day ceftriaxone therapy: 228) received dexamethasone therapy.*<br><br>*Reported for whole study, not based on causative organism<br><br>Case-fatality: 4.1% |

1  *AIDS: acquired immunodeficiency syndrome; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; SD: standard deviation; RCT: randomised controlled trial*

2  **Outcomes**

3  **5-day ceftriaxone therapy versus 10-day ceftriaxone therapy: All-cause mortality, any long-term neurological impairment,**
4  **developmental delay, hearing impairment, serious intervention-related adverse effects and CSF sterilisation**

| Outcome | 5-days ceftriaxone therapy, N = 496 | 10-days ceftriaxone therapy, N = 508 |
| --- | --- | --- |
| **All-cause mortality (up to 6 months after discharge)**<br><br>Custom value | 12/154 | 9/181 |
| **Any long-term neurological impairment (neurological sequelae including motor deficit, cranial nerve palsy and afebrile seizures; up to 6 months after discharge)**<br><br>Custom value | 21/496 | 30/508 |
| **Any long-term neurological impairment (visual loss; up to 6 months after discharge)**<br><br>Custom value | 4/496 | 10/508 |
| **Developmental delay (assessed using the age and stages questionnaire; up to 6 months after discharge)**<br><br>Custom value | 25/496 | 33/508 |

| Outcome | 5-days ceftriaxone therapy, N = 496 | 10-days ceftriaxone therapy, N = 508 |
|---|---|---|
| **Hearing impairment (up to 6 months after discharge)**<br><br>Custom value | 105/496 | 106/508 |
| **Serious intervention-related adverse effects (adverse events to the study drug; up to 6 months after discharge)**<br><br>Custom value | 0/496 | 0/508 |
| **CSF sterilisation (positive cerebrospinal fluid or blood cultures on days 6-40)**<br><br>Custom value | 2/154 | 3/181 |

1  *CSF: cerebrospinal fluid*

2  **Critical appraisal - Cochrane RoB2**

| Section | Question | Answer |
|---|---|---|
| Domain 1: Bias arising from the randomisation process | Risk of bias judgement for the randomisation process | Low<br>(Computer-generated randomisation, process of allocation controlled by an external unit, sealed opaque envelopes used for allocation concealment. No substantial differences between groups at baseline.) |
| Domain 2a: Risk of bias due to deviations from the intended interventions (effect of assignment to intervention) | Risk of bias for deviations from the intended interventions (effect of assignment to intervention) | Low<br>(Participants and intervention staff were not aware of intervention. Appropriate analysis was used.) |
| Domain 3. Bias due to missing outcome data | Risk-of-bias judgement for missing outcome data | Some concerns<br>(Loss to follow up greater in 10-day ceftriaxone therapy compared with other arm for all outcomes (5.3% vs 4% on day 40; 11% vs 6.5% at 6-month follow-up) and could be related to participants' health status or death.) |

| Section | Question | Answer |
|---|---|---|
| Domain 4. Bias in measurement of the outcome | Risk-of-bias judgement for measurement of the outcome | Low/High<br>(Methods of measuring the outcomes were appropriate, and no difference in measurement of the outcomes between intervention groups. No information if outcome assessors were blinded to intervention status. Low risk for all-cause mortality, hearing impairment, CSF sterilisation and serious intervention-related adverse effects outcomes as outcome measurement would not be influenced by knowledge of assigned intervention, and high risk for neurological impairment, including visual loss, and developmental delay outcomes as they are somewhat subjective and may be influenced by knowledge of assigned intervention.) |
| Domain 5. Bias in selection of the reported result | Risk-of-bias judgement for selection of the reported result | Low<br>(There is clear evidence that all eligible reported results for the outcome correspond to all intended outcome measurements and analyses in the protocol.) |
| Overall bias and Directness | Risk of bias judgement | Some concerns for all-cause mortality, hearing impairment, CSF sterilisation and serious intervention-related adverse effects.<br><br>High risk for any long-term neurological impairment and developmental delay. |
| Overall bias and Directness | Overall Directness | Indirectly applicable<br>(All outcomes other than all-cause mortality and CSF sterilisation, data is presented for the whole study rather than the subgroup of interest. Therefore, population is very seriously indirect (<50% had bacterial meningitis caused by organism of interest). Also, developmental delay is an indirect outcome (because no indication of severity).) |
| Overall bias and Directness | Risk of bias variation across outcomes | Yes, see "Risk of bias judgement" cell above. |

1  *CSF: cerebrospinal fluid; ; RoB: risk of bias; SD: standard deviation*

2

1 # Appendix E  Forest plots

2 **Forest plots for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis caused by**
3 **Streptococcus pneumoniae?**

4 No meta-analysis was conducted for this review question and so there are no forest plots.

1

# Appendix F  GRADE tables

**GRADE tables for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis caused by Streptococcus pneumoniae?**

**Table 5:  Evidence profile for comparison: 5-day ceftriaxone therapy versus 10-day ceftriaxone therapy**

| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | 5-days ceftriaxone therapy | 10-days ceftriaxone therapy | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Quality assessment | | | | No of patients | | Effect | | |
| **All-cause mortality: babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 12/154 (7.8%) | 9/181 (5%) | RR 1.57 (0.68 to 3.62) | 28 more per 1000 (from 16 fewer to 130 more) | VERY LOW | CRITICAL |
| **Any long-term neurological impairment (neurological sequelae including motor deficit, cranial nerve palsy and afebrile seizures): babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | very Serious[3] | no serious inconsistency | very serious[4] | Serious[5] | none | 21/496 (4.2%) | 30/508 (5.9%) | RR 0.72 (0.42 to 1.23) | 17 fewer per 1000 (from 34 fewer to 14 more) | VERY LOW | CRITICAL |
| **Any long-term neurological impairment (visual loss): babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | very Serious[3] | no serious inconsistency | very serious[6] | very serious[7] | none | 4/496 (0.8%) | 10/508 (2%) | RR 0.41 (0.13 to 1.3) | 12 fewer per 1000 (from 17 fewer to 6 more) | VERY LOW | CRITICAL |
| **Developmental delay (assessed using the age and stages questionnaire): babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |

| 1 Molyneux, 2011 | randomised trials | very Serious[3] | no serious inconsistency | very serious[8] | very serious[7] | none | 25/496 (5%) | 33/508 (6.5%) | RR 0.78 (0.47 to 1.29) | 14 fewer per 1000 (from 34 fewer to 19 more) | VERY LOW | CRITICAL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Hearing impairment: babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | serious[1] | no serious inconsistency | very serious[6] | very serious[7] | none | 105/496 (21.2%) | 106/508 (20.9%) | RR 1.01 (0.8 to 1.29) | 2 more per 1000 (from 42 fewer to 61 more) | VERY LOW | IMPORTANT |
| **Serious intervention-related adverse effects (adverse events to the study drug): babies and children (up to 6 months after discharge)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | serious[1] | no serious inconsistency | very serious[6] | no serious imprecision | none | 0/496 (0%) | 0/508 (0%) | RD 0.00 (-0.0039 to 0.0039) | 0 fewer per 1000 (from 3.9 fewer to 3.9 more)[9] | VERY LOW | IMPORTANT |
| **CSF sterilisation (positive cerebrospinal fluid or blood cultures): babies and children (on days 6-40)** | | | | | | | | | | | | |
| 1 Molyneux, 2011 | randomised trials | serious[1] | no serious inconsistency | very serious[10] | very serious[2] | none | 2/154 (1.3%) | 3/181 (1.7%) | RR 0.78 (0.13 to 4.63) | 4 fewer per 1000 (from 14 fewer to 60 more) | VERY LOW | IMPORTANT |

CI: confidence interval; CSF: cerebrospinal fluid; RD: risk difference, RR: risk ratio

[1] Serious risk of bias in the evidence contributing to the outcomes as per RoB 2

[2] <150 events

[3] Very serious risk of bias in the evidence contributing to the outcomes as per RoB 2

[4] Outcome is indirect as it is a composite outcome including afebrile seizures, and population is very indirect due to 66.6% of population with meningitis caused by organisms other than Streptococcus pneumoniae

[5] 95% CI crosses 1 MID

[6] Population is very indirect due to 66.6% of population with meningitis caused by organisms other than Streptococcus pneumoniae

[7] 95% CI crosses 2 MIDs

[8] Outcome is indirect as it is a composite outcome that could include mild or moderate developmental delay and population is very indirect due to 66.6% of population with meningitis caused by organisms other than Streptococcus pneumonia

[9] Absolute effect calculated based on risk difference

[10] Outcome is indirect as it is a composite outcome including positive blood culture

1 # Appendix G Economic evidence study selection

2 **Study selection for: What antibiotic treatment regimens are effective in treating**
3 **bacterial meningitis caused by Streptococcus pneumoniae?**

4 A global economic search was undertaken for the whole guideline, but no economic
5 evidence was identified which was applicable to this review question (see Figure 2).

6 **Figure 2: Study selection flow chart**

```
                        ┌─────────────────────────┐
                        │   Titles and abstracts   │
                        │   identified, N= 2578    │
                        └───────────┬─────────────┘
                ┌───────────────────┴────────────────────┐
     ┌──────────────────────┐              ┌──────────────────────────┐
     │  Full copies retrieved│              │   Excluded, N=2575        │
     │  and assessed for     │              │  (not relevant population,│
     │  eligibility, N= 3    │              │  design, intervention,    │
     └──────────┬───────────┘              │  comparison, outcomes,    │
                │                           │  unable to retrieve)      │
     ┌──────────┴──────────┐                └──────────────────────────┘
┌───────────────────┐  ┌────────────────────┐
│ Publications       │  │ Publications        │
│ excluded from      │  │ included in         │
│ guideline, N= 2    │  │ guideline, N= 1     │
└───────────────────┘  └──────────┬─────────┘
                          ┌────────┴─────────┐
              ┌──────────────────┐  ┌──────────────────┐
              │ Publications not │  │ Publications      │
              │ relevant to this │  │ included in this  │
              │ review, N= 1     │  │ review, N= 0      │
              └──────────────────┘  └──────────────────┘
```

7

8

9

1 # Appendix H  Economic evidence tables

2 **Economic evidence tables for review question: What antibiotic treatment**
3 **regimens are effective in treating bacterial meningitis caused by Streptococcus**
4 **pneumoniae?**

5 No evidence was identified which was applicable to this review question.

6

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

# 1 Appendix I  Economic model

2 **Economic model for review question: What antibiotic treatment regimens are**
3 **effective in treating bacterial meningitis caused by Streptococcus**
4 **pneumoniae?**

5 No economic analysis was conducted for this review question.

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management:
evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus
pneumoniae DRAFT (September 2023)

1

## Appendix J  Excluded studies

**Excluded studies for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis caused by Streptococcus pneumoniae?**

**Excluded effectiveness studies**

The excluded studies table only lists the studies that were considered and then excluded at the full-text stage for this review (N=15) and not studies (N=176) that were considered and then excluded from the search at the full-text stage as per the PRISMA diagram in Appendix C for the other review questions in the same search.

**Table 8:  Excluded studies and reasons for their exclusion**

| Study | Code [Reason] |
| --- | --- |
| Ahmed, A. (1997) A critical evaluation of vancomycin for treatment of bacterial meningitis. Pediatric Infectious Disease Journal 16(9): 895-903 | Study design does not meet inclusion criteria |
| Arditi, M., Mason Jr, E. O., Bradley, J. S. et al. (1998) Three-year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 102(5): 1087-1097 | No comparison of interest |
| Aronin, Steven I. (2002) Current pharmacotherapy of pneumococcal meningitis. Expert opinion on pharmacotherapy 3(2): 121-9 | Study design does not meet inclusion criteria |
| Baddour, Larry M., Yu, Victor L., Klugman, Keith P. et al. (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. American journal of respiratory and critical care medicine 170(4): 440-4 | Population does not meet inclusion criteria |
| Bradley, J. S. and Scheld, W. M. (1997) The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: Current antibiotic therapy in the 1990s. Clinical Infectious Diseases 24(suppl2): S213-S221 | Study design does not meet inclusion criteria |
| Buckingham, Steven C., McCullers, Jonathan A., Lujan-Zilbermann, Jorge et al. (2006) Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics 117(5): 1688-94 | No comparison of interest |
| Congeni, B. L. (1984) Comparison of ceftriaxone and traditional therapy of bacterial meningitis. | Population does not meet inclusion criteria |

| | |
|---|---|
| Antimicrobial agents and chemotherapy 25(1): 40-44 | |
| Fitzgerald, Deirdre and Waterer, Grant W. (2019) Invasive Pneumococcal and Meningococcal Disease. Infectious disease clinics of North America 33(4): 1125-1141 | Study design does not meet inclusion criteria |
| Goldwater, Paul N. (2005) Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. International journal of antimicrobial agents 26(5): 408-11 | No outcomes of interest |
| Harbarth, S., Garbino, J., Pugin, J. et al. (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 24(10): 688-90 | Population does not meet inclusion criteria |
| Heidary, Mohsen, Khosravi, Azar Dohkt, Khoshnood, Saeed et al. (2018) Daptomycin. The Journal of antimicrobial chemotherapy 73(1): 1-11 | Study design does not meet inclusion criteria |
| Kaplan, Sheldon L. (2002) Management of pneumococcal meningitis. The Pediatric infectious disease journal 21(6): 589-4 | Study design does not meet inclusion criteria |
| Peltola, H.; Anttila, M.; Renkonen, O. V. (1989) Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. Lancet (london, england) 1(8650): 1281-1287 | Population does not meet inclusion criteria |
| Roine, I., Ledermann, W., Foncea, L. M. et al. (2000) Randomized trial of four vs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery. Pediatric infectious disease journal 19(3): 219-222 | Population does not meet inclusion criteria |
| Singhi, P., Kaushal, M., Singhi, S. et al. (2002) Seven days vs. 10 days ceftriaxone therapy in bacterial meningitis. Journal of tropical pediatrics 48(5): 273-279 | Population does not meet inclusion criteria |

1

## Excluded economic studies

No studies were identified which were applicable to this review question.

1

2

3

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: evidence reviews for antibiotics for bacterial meningitis caused by Streptococcus pneumoniae DRAFT (September 2023)

# Appendix K  Research recommendations – full details

**Research recommendations for review question: What antibiotic treatment regimens are effective in treating bacterial meningitis caused by Streptococcus pneumoniae?**

No research recommendation was made for this review.